SLAM
RXRX icon

Swiss Life Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Swiss Life Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.5K Buy
26,831
+3,672
+16% +$12.2K ﹤0.01% 1590
2026
Q1 		$71.1K Buy
23,159
+6,109
+36% +$23.6K ﹤0.01% 1473
2025
Q4 		$69.7K Buy
17,050
+3,657
+27% +$18.1K ﹤0.01% 1357
2025
Q3 		$65.4K Buy
+13,393
New +$70.3K ﹤0.01% 1168

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Swiss Life Asset Management's RXRX Position: Q2 2026 in Review

Swiss Life Asset Management increased its Recursion Pharmaceuticals (RXRX) stake by 16% in Q2 2026, buying an estimated $12.2K and bringing the position to 26,831 shares worth $98.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1590.

Swiss Life Asset Management first reported a position in RXRX in Q3 2025 and has held it in 4 quarters since. 236 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Swiss Life Asset Management held 26,831 shares of Recursion Pharmaceuticals worth $98.5K as of Q2 2026.
  • Swiss Life Asset Management bought 3,672 Recursion Pharmaceuticals shares in Q2 2026, an estimated $12.2K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1590 holding.
  • Swiss Life Asset Management first reported a position in Recursion Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 236 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.